Parenteral formulation of an antileishmanial drug candidate--tackling poor solubility, chemical instability, and polymorphism.

[1]  R. Censi,et al.  A new nanospray drying method for the preparation of nicergoline pure nanoparticles , 2012, Journal of Nanoparticle Research.

[2]  Elaine Merisko-Liversidge,et al.  Nanosizing for oral and parenteral drug delivery: a perspective on formulating poorly-water soluble compounds using wet media milling technology. , 2011, Advanced drug delivery reviews.

[3]  Heike Bunjes,et al.  Lipid nanoparticles for the delivery of poorly water‐soluble drugs , 2010, The Journal of pharmacy and pharmacology.

[4]  G. Van den Mooter,et al.  Review: physical chemistry of solid dispersions , 2009 .

[5]  S. Yalkowsky,et al.  Predicting aqueous solubility: the role of crystallinity. , 2009, Current drug metabolism.

[6]  J. Comer,et al.  Using measured pKa, LogP and solubility to investigate supersaturation and predict BCS class. , 2008, Current drug metabolism.

[7]  J. Torrado,et al.  Amphotericin B formulations and drug targeting. , 2008, Journal of pharmaceutical sciences.

[8]  Christina Johanna Reichwald.  Eine neue Variante der Heck-Reaktion zur Darstellung antileishmanieller Paullone , 2008 .

[9]  C. Kunick,et al.  2-(3-aryl-3-oxopropen-1-yl)-9-tert-butyl-paullones: a new antileishmanial chemotype. , 2008, Journal of medicinal chemistry.

[10]  V. Stella,et al.  Prodrug strategies to overcome poor water solubility. , 2007, Advanced drug delivery reviews.

[11]  Simone Kohfeld.  Untersuchungen zur Synthese, biologischen Aktivität und Stabilität von Paullonen und verwandten d-anellierten [1]Benzazepinonen , 2006 .

[12]  H. Bunjes,et al.  Supercooled Smectic Nanoparticles: A Potential Novel Carrier System for Poorly Water Soluble Drugs , 2004, Pharmaceutical Research.

[13]  P. Constantinides,et al.  Tocol emulsions for drug solubilization and parenteral delivery. , 2004, Advanced drug delivery reviews.

[14]  Michael J Cima,et al.  High-throughput crystallization: polymorphs, salts, co-crystals and solvates of pharmaceutical solids. , 2004, Advanced drug delivery reviews.

[15]  E. D. de Bruijn,et al.  Pharmacokinetics and tolerance of intravenous and intramuscular phylloquinone (vitamin K1) mixed micelles formulation. , 2003, British journal of clinical pharmacology.

[16]  J Verweij,et al.  Cremophor EL: the drawbacks and advantages of vehicle selection for drug formulation. , 2001, European journal of cancer.

[17]  J. Bauer,et al.  Ritonavir: An Extraordinary Example of Conformational Polymorphism , 2001, Pharmaceutical Research.

[18]  C. Lipinski.  Drug-like properties and the causes of poor solubility and poor permeability. , 2000, Journal of pharmacological and toxicological methods.

[19]  H. Inoue,et al.  Antitumorigenic activities of chalcones (II). Photo-isomerization of chalcones and the correlation with their biological activities. , 1997, Biological & pharmaceutical bulletin.

[20]  O. Buchardt,et al.  Photochemical cis-trans isomerization of furylacryloylpeptides and their different kinetic behavior as substrates for carboxypeptidase Y. , 1991, Analytical biochemistry.

[21]  V. Stella,et al.  Low-melting phenytoin prodrugs as alternative oral delivery modes for phenytoin: a model for other high-melting sparingly water-soluble drugs. , 1983, Journal of pharmaceutical sciences.

[22]  Y. Rahman,et al.  Differential uptake of liposomes varying in size and lipid composition by parenchymal and kupffer cells of mouse liver. , 1982, Life sciences.

[23]  R. New,et al.  Antileishmanial activity of amphotericin and other antifungal agents entrapped in liposomes. , 1981, The Journal of antimicrobial chemotherapy.

[24]  C. Bucana,et al.  Biochemical, morphological, and ultrastructural studies on the uptake of liposomes by murine macrophages. , 1981, Cancer research.

[25]  H. Bunjes,et al.  Passive loading of lipid nanoparticles with poorly water soluble drugs , 2011 .

[26]  S. Ackermann.  Untersuchungen zur Synthese von Bottromycin B2 , 2008 .

[27]  H. Bunjes,et al.  Transformation of vesicular into cubic nanoparticles by autoclaving of aqueous monoolein/poloxamer dispersions. , 2006, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.

[28]  T. Allen.  Liposomal drug formulations. Rationale for development and what we can expect for the future. , 1998, Drugs.

[29]  F. Krahn,et al.  Relations between several polymorphic forms and the dihydrate of carbamazepine. , 1987, Pharmaceutica acta Helvetiae.